



ESC 31 August 2015 Hot Line III - Diabetes mellitus/Pharmacology

<u>Evaluation of LIX</u>isenatide in <u>Acute Coronary Syndrome (ELIXA)</u>

Eldrin F. Lewis, MD, MPH Associate Professor of Medicine Harvard Medical School Brigham and Women's Hospital

ELIXA Trial Executive Committee: Rafael Diaz, Kenneth Dickstein, Hertzel Gerstein, Lars Køber, Eldrin Lewis, Aldo Maggioni, John McMurray, Marc Pfeffer (Chair), Jeffrey Probstfield, Matthew Riddle, Scott Solomon, Jean-Claude Tardif

on behalf of the ELIXA Investigators

ClinTrials.gov NCT01147250



Hot Line presentation


DECLARATION OF INTEREST

- Research contracts
- Consulting/Royalties/Owner/ Stockholder of a healthcare company



#esccongress

1° Outcome (CV Death, MI, Stroke or UA)




ESC CONGRESS

Hot Line presentation

Lixisenatide & CV Outcomes






ESC CONGRESS

Hot Line presentation

Heart Failure Hospitalization (by History of HF)

LONDON 2015





Hot Line presentation



ELIXA Summary

- Demonstrates CV safety of lixisenatide (as defined by FDA Guidance), but not superiority in reducing CV events
- Additional analyses indicate safety with respect to heart failure events as well as death
- Neutral effects seen across wide spectrum of heart failure risk



Hot Line presentation



Hot Line presentation




Results:

Biomarker changes with lixisenatide vs placebo

- 1) HbA1c (absolute value) was 0.27% lower* (with similar hypoglycemia events)
- 2) Weight change was 0.7kg less* (with more frequent discontinuation due to GI complaints 4.9% vs. 1.2%*)
- 3) SBP was 0.8 mmHg less*
- 4) Albuminuria increased less, 24% vs 34%*
- 5) Heart rate was increased 0.4 bpm*
 - * p<0.05



Mortality* following HF Hosp



ELIXA

Clinical Outcomes by BNP*

BNP Quartile	Primary Outcome	Heart Failure	CVD + HF
	Incidence Rate (per 100 patient-years)		
1 (≤ 50 pg/mL)	3.2	0.2	0.7
2 (51-107 pg/mL)	4.4	1.0	1.8
3 (108-219 pg/mL)	5.7	1.6	3.0
4 (≥ 220 pg/mL)	13.4	5.2	10.8

*no significant interactions between BNP quartile and treatment effect HR

ESC CONGRESS

LONDON 2015




www.escardio.org/ESC2015

EL

CV Death + Heart Failure Hospitalization (by history of HF)

LONDON 2015





Hot Line presentation